Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 22:03 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableRecruitingINTERVENTIONAL

Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus

ClinicalTrials.gov · NCT05662189 · Registry updated: 2025-03-18

Condition / research focus: Type1diabetes; Type2diabetes; Pre Diabetes; Hyperinsulinism
Sponsor: Azienda Ospedaliero-Universitaria di Parma
Countries with listed sites: Italy
Registry dates and results: Start: 2022-03-15. Completion: 2025-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

68Ga-exendin-4 (drug)
mixed meal test (other)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Azienda Ospedaliero Universitaria di Parma
Parma, Pr, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

ClinicalTrials.gov · NCT04172441 · Registry updated: 2025-03-14

Condition / research focus: Congenital Hyperinsulinism
Sponsor: Zealand Pharma
Countries with listed sites: Germany · Israel · United Kingdom · United States
Registry dates and results: Start: 2020-06-19. Completion: 2022-03-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

dasiglucagon (drug) — also listed as: ZP4207
Placebo (drug)

Where the study takes place — 6 listed sites

Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Cook Children's Medical Center
Fort Worth, Texas, United States
Site recruitment: Not reported
University Children's Hospital
Düsseldorf, Germany
Site recruitment: Not reported
University Hospital, Magdeburg
Magdeburg, Germany
Site recruitment: Not reported
Hadassah Medical Center
Jerusalem, Israel
Site recruitment: Not reported
Manchester University NHS Foundation Trust
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableWithdrawnINTERVENTIONAL

An Exploratory Study of 68Ga-DOTA-SEMA in Preoperative Precise Imaging of Patients with Glucagon-Like Peptide-1 Receptor (GLP1R) Positive Insulinomas

ClinicalTrials.gov · NCT06759740 · Registry updated: 2025-03-14

Condition / research focus: Hypoglycaemia
Sponsor: The Affiliated Hospital Of Southwest Medical University
Countries with listed sites: China
Registry dates and results: Start: 2026-01. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

68Ga-DOTA-SEMA (radiation)

Where the study takes place — 1 listed sites

The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

ClinicalTrials.gov · NCT06515418 · Registry updated: 2025-03-13

Condition / research focus: Obesity
Sponsor: BioAge Labs, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2024-06-27. Completion: 2025-02-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral Azelaprag (BGE-105) (drug) — also listed as: BGE-105
Oral Placebo for Azelaprag (BGE-105) (drug) — also listed as: Placebo
Tirzepatide (drug)
Tirzepatide Placebo (drug)

Where the study takes place — 14 listed sites

Site 110
Mesa, Arizona, United States
Site recruitment: Not reported
Site 107
Los Angeles, California, United States
Site recruitment: Not reported
Site 103
Montclair, California, United States
Site recruitment: Not reported
Site 105
Spring Valley, California, United States
Site recruitment: Not reported
Site 100
Louisville, Kentucky, United States
Site recruitment: Not reported
Site 101
Marrero, Louisiana, United States
Site recruitment: Not reported
Site 112
Boston, Massachusetts, United States
Site recruitment: Not reported
Site 111
Troy, Michigan, United States
Site recruitment: Not reported
Site 113
City of Saint Peters, Missouri, United States
Site recruitment: Not reported
Site 106
Butte, Montana, United States
Site recruitment: Not reported
Site 109
Fargo, North Dakota, United States
Site recruitment: Not reported
Site 108
Beachwood, Ohio, United States
Site recruitment: Not reported
Site 102
Dallas, Texas, United States
Site recruitment: Not reported
Site 104
St. George, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

ClinicalTrials.gov · NCT03158805 · Registry updated: 2025-03-12

Condition / research focus: Bipolar Disorder; Obesity
Sponsor: Lindner Center of HOPE
Countries with listed sites: United States
Registry dates and results: Start: 2017-04-26. Completion: 2023-01-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LIRAGLUTIDE (drug) — also listed as: Saxenda
Placebo (other)

Where the study takes place — 1 listed sites

Lindner Center of HOPE
Mason, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies

ClinicalTrials.gov · NCT05920889 · Registry updated: 2025-03-07

Condition / research focus: Stroke; Stroke, Acute; Stroke, Ischemic; Brain Diseases
Sponsor: Chinese University of Hong Kong
Countries with listed sites: China · Hong Kong
Registry dates and results: Start: 2023-08-01. Completion: 2024-10-25 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 2 listed sites

Linyi People's Hospital
Linyi, Shangdong, China
Site recruitment: Not reported
Chinese University of Hong Kong
Hong Kong, Hong Kong
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Active, not recruitingINTERVENTIONAL

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

ClinicalTrials.gov · NCT06565611 · Registry updated: 2025-03-06

Condition / research focus: Obesity
Sponsor: Palatin Technologies, Inc
Countries with listed sites: United States
Registry dates and results: Start: 2024-08-05. Completion: 2025-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

bremelanotide (drug)
tirzepatide (drug)

Where the study takes place — 4 listed sites

University Clinical Research-DeLand LLC, d/b/a Accel Research
DeLand, Florida, United States
Site recruitment: Not reported
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported
Coastal Carolina Research Center
North Charleston, South Carolina, United States
Site recruitment: Not reported
Lynn Institute of Chattanooga
Chattanooga, Tennessee, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Chronic Dorzagliatin on Insulin and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes

ClinicalTrials.gov · NCT06671340 · Registry updated: 2025-03-04

Condition / research focus: Diabetes Mellitus; Prediabetes / Type 2 Diabetes
Sponsor: Elaine Chow
Countries with listed sites: Hong Kong
Registry dates and results: Start: 2025-04-02. Completion: 2026-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dorzagliatin (drug)

Where the study takes place — 1 listed sites

Phase 1 Clinical Trial Centre
Hong Kong, Hong Kong
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Liraglutide and Peripheral Artery Disease

ClinicalTrials.gov · NCT04881110 · Registry updated: 2025-03-03

Condition / research focus: Type 2 Diabetes; Peripheral Arterial Disease
Sponsor: University of Campania Luigi Vanvitelli
Countries with listed sites: Italy
Registry dates and results: Start: 2021-02-01. Completion: 2022-12-31 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Intervention group
Control (other) — also listed as: Control group

Where the study takes place — 1 listed sites

Unit of Endocrinology and Metabolic Diseases and Unit of Diabetes, University of Campania Luigi Vanvitelli
Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

ClinicalTrials.gov · NCT05501483 · Registry updated: 2025-02-26

Condition / research focus: Type 2 Diabetes
Sponsor: Karolinska Institutet
Countries with listed sites: Sweden
Registry dates and results: Start: 2023-02-08. Completion: 2032-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pioglitazone 45 mg (drug)
Empagliflozin 25 MG (drug)
Semaglutide 7 MG (drug)

Where the study takes place — 1 listed sites

Karolinska University Hospital
Stockholm, Sweden
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4WithdrawnINTERVENTIONAL

Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity

ClinicalTrials.gov · NCT06009653 · Registry updated: 2025-02-25

Condition / research focus: Obesity; Metabolic Disease
Sponsor: Washington University School of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2023-09-13. Completion: 2024-05-29 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Standard Care (behavioral)
Culturally-tailored dietary and behavioral intensive lifestyle intervention (behavioral)
Placebo (drug)
Tirzepatide (drug)

Where the study takes place — 1 listed sites

Sansum Diabetes Research Institute
Santa Barbara, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects

ClinicalTrials.gov · NCT03682172 · Registry updated: 2025-02-17

Condition / research focus: Effect of Glucagon-like Peptide 2 on Gallbladder Motility
Sponsor: Steno Diabetes Center Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2018-05-01. Completion: 2020-07-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-2 (1pmol/kg/min) (drug)
GLP-2 (10pmol/kg/min) (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen
Hellerup, Capital Region, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

ClinicalTrials.gov · NCT05203237 · Registry updated: 2025-02-17

Condition / research focus: Weight Loss; NASH
Sponsor: Viking Therapeutics, Inc.
Countries with listed sites: Australia
Registry dates and results: Start: 2021-12-14. Completion: 2024-12-03 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

VK2735 (biological)
Placebo (biological)
VK2735 Placebo (drug)
VK2735 Drug (drug)

Where the study takes place — 1 listed sites

Viking Clinical Site
Adelaide, South Australia, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes

ClinicalTrials.gov · NCT06825182 · Registry updated: 2025-02-13

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Nanjing First Hospital, Nanjing Medical University
Countries with listed sites: China
Registry dates and results: Start: 2024-11-07. Completion: 2025-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Outpatient newly diagnosed type 2 diabetes subjects (drug)
Inpatient newly diagnosed type 2 diabetes subjects (drug)

Where the study takes place — 1 listed sites

Nanjing First Hostital
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists

ClinicalTrials.gov · NCT06818292 · Registry updated: 2025-02-10

Condition / research focus: Healthy
Sponsor: Nils Opel
Countries with listed sites: Germany
Registry dates and results: Start: 2024-10-21. Completion: 2024-12-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (biological) — also listed as: GLP-1 Agonist
Placebo (biological)

Where the study takes place — 1 listed sites

Department of Psychiatry and Psychotherapy, University Hospital Jena
Jena, Thuringia, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2RecruitingINTERVENTIONAL

Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT05268237 · Registry updated: 2025-02-06

Condition / research focus: Diabete Type 2
Sponsor: Biolingus
Countries with listed sites: Hong Kong
Registry dates and results: Start: 2023-04-25. Completion: 2026-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Clinical Trials Unit, Chinese University of Hong Kong
Hong Kong, Hong Kong
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

ClinicalTrials.gov · NCT04166773 · Registry updated: 2025-01-24

Condition / research focus: Nonalcoholic Steatohepatitis
Sponsor: Eli Lilly and Company
Countries with listed sites: Belgium · France · Israel · Italy · Japan · Mexico · Poland · Spain · United Kingdom · United States
Registry dates and results: Start: 2019-11-19. Completion: 2024-01-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)

Where the study takes place — 112 listed sites

University of Alabama-The Kirklin Clinic
Birmingham, Alabama, United States
Site recruitment: Not reported
Synexus Clinical Research US, Inc.
Chandler, Arizona, United States
Site recruitment: Not reported
Fresno Clinical Research Center
Fresno, California, United States
Site recruitment: Not reported
National Research Institute - Huntington Park
Huntington Park, California, United States
Site recruitment: Not reported
UCSD - Altman Clinical and Translational Research Institute (ACTRI)
La Jolla, California, United States
Site recruitment: Not reported
National Research Institute - Wilshire
Los Angeles, California, United States
Site recruitment: Not reported
Catalina Research Institute, LLC
Montclair, California, United States
Site recruitment: Not reported
Diabetes Medical Center of California
Northridge, California, United States
Site recruitment: Not reported
Velocity Clinical Research, Panorama City
Panorama City, California, United States
Site recruitment: Not reported
Inland Empire Clinical Trials, LLC
Rialto, California, United States
Site recruitment: Not reported
Velocity Clinical Research, Santa Ana
Santa Ana, California, United States
Site recruitment: Not reported
Excel Medical Clinical Trials
Boca Raton, Florida, United States
Site recruitment: Not reported
Alliance for Multispecialty Research, LLC
Coral Gables, Florida, United States
Site recruitment: Not reported
Research Centers of America ( Hollywood )
Hollywood, Florida, United States
Site recruitment: Not reported
East Coast Institute for Research, LLC
Jacksonville, Florida, United States
Site recruitment: Not reported
IHS Health Research
Kissimmee, Florida, United States
Site recruitment: Not reported
Accel Research Sites - Maitland Clinical Research Unit
Maitland, Florida, United States
Site recruitment: Not reported
Clinical Pharmacology of Miami
Miami, Florida, United States
Site recruitment: Not reported
The Center for Digestive Health
Orlando, Florida, United States
Site recruitment: Not reported
Synexus Clinical Research US, Inc.
Orlando, Florida, United States
Site recruitment: Not reported
Synexus Clinical Research US, Inc.
The Villages, Florida, United States
Site recruitment: Not reported
Synexus Clinical Research
Chicago, Illinois, United States
Site recruitment: Not reported
Indiana University Health Hospital
Indianapolis, Indiana, United States
Site recruitment: Not reported
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
Site recruitment: Not reported
Cotton O'Neil Clinical Research Center
Topeka, Kansas, United States
Site recruitment: Not reported
Alliance for Multispecialty Research, LLC
Wichita, Kansas, United States
Site recruitment: Not reported
Tandem Clinical Research
Marrero, Louisiana, United States
Site recruitment: Not reported
The National Diabetes & Obesity Research Institute
Biloxi, Mississippi, United States
Site recruitment: Not reported
Southern Therapy and Advanced Research (STAR) LLC
Jackson, Mississippi, United States
Site recruitment: Not reported
Buffalo Clinical and Translational Research Center
Buffalo, New York, United States
Site recruitment: Not reported
NYU Langone Health
New York, New York, United States
Site recruitment: Not reported
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Site recruitment: Not reported
Montefiore Medical Center
The Bronx, New York, United States
Site recruitment: Not reported
Diabetes & Endocrinology Consultants, PC
Morehead City, North Carolina, United States
Site recruitment: Not reported
Geisinger Medical Center
Danville, Pennsylvania, United States
Site recruitment: Not reported
WR-Clinsearch, LLC
Chattanooga, Tennessee, United States
Site recruitment: Not reported
Dallas Diabetes Research Center
Dallas, Texas, United States
Site recruitment: Not reported
Radiant Research - Dallas North
Dallas, Texas, United States
Site recruitment: Not reported
Liver Center of Texas, PLLC
Dallas, Texas, United States
Site recruitment: Not reported
Texoma Medical Center
Denison, Texas, United States
Site recruitment: Not reported
Texas Diabetes & Endocrinology, P.A.
Round Rock, Texas, United States
Site recruitment: Not reported
American Research Corporation at Texas Liver Institute
San Antonio, Texas, United States
Site recruitment: Not reported
Synexus Clinical Research US, Inc.
San Antonio, Texas, United States
Site recruitment: Not reported
Endeavor Clinical Trials
San Antonio, Texas, United States
Site recruitment: Not reported
National Clinical Research, Inc
Richmond, Virginia, United States
Site recruitment: Not reported
Virginia Commonwealth University (VCU) Medical Center
Richmond, Virginia, United States
Site recruitment: Not reported
Harborview Medical Center/University of Washington
Seattle, Washington, United States
Site recruitment: Not reported
Antwerp University Hospital
Edegem, Antwerpen, Belgium
Site recruitment: Not reported
UZ Brussel
Brussels, Bruxelles-Capitale, Région de, Belgium
Site recruitment: Not reported
UZ Gent
Ghent, Oost-Vlaanderen, Belgium
Site recruitment: Not reported
UZ Leuven
Leuven, Vlaams-Brabant, Belgium
Site recruitment: Not reported
AZ Delta vzw
Roeselare, West-Vlaanderen, Belgium
Site recruitment: Not reported
CHU Bordeaux Haut-Leveque
Pessac, Aquitaine, France
Site recruitment: Not reported
Groupe Hospitalier Mutualiste Les Portes du Sud
Vénissieux, Auvergne-Rhône-Alpes, France
Site recruitment: Not reported
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren
Limoges, Haute-Vienne, France
Site recruitment: Not reported
Centre Hospitalier Universitaire d'Angers
Angers, Maine-et-Loire, France
Site recruitment: Not reported
Centre Hospitalier Lyon Sud
Pierre-Bénite, Rhône, France
Site recruitment: Not reported
Pitie Salpetriere University Hospital
Paris, France
Site recruitment: Not reported
Hôpital Saint Antoine
Paris, France
Site recruitment: Not reported
Sheba Medical Center
Ramat Gan, Central District, Israel
Site recruitment: Not reported
Hadassah Medical Center
Jerusalem, Jerusalem, Israel
Site recruitment: Not reported
Shaare Zedek Medical Center
Jerusalem, Jerusalem, Israel
Site recruitment: Not reported
Rambam Health Care Campus
Haifa, Northern District, Israel
Site recruitment: Not reported
Galilee Medical Center
Nahariya, Northern District, Israel
Site recruitment: Not reported
Carmel Hospital
Haifa, Israel
Site recruitment: Not reported
A.O.U. Policlinico Paolo Giaccone
Palermo, Sicily, Italy
Site recruitment: Not reported
Azienda Ospedaliero Universitaria Ospedali Riuniti Di Foggia
Foggia, Italy
Site recruitment: Not reported
Ospedale Santa Maria Goretti
Latina, Italy
Site recruitment: Not reported
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
Site recruitment: Not reported
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
Torino, Italy
Site recruitment: Not reported
Aichi Medical University Hospital
Nagakute-shi, Aichi-ken, Japan
Site recruitment: Not reported
JCHO Hokkaido Hospital
Sapporo, Hokkaido, Japan
Site recruitment: Not reported
Yokohama City University Hospital
Yokohama, Kanagawa, Japan
Site recruitment: Not reported
National Hospital Organization Yokohama Medical Center
Yokohama, Kanagawa, Japan
Site recruitment: Not reported
JADECOM Nara City Hospital
Nara, Nara, Japan
Site recruitment: Not reported
Hirakata kohsai Hospital
Higashi-cho, Hirakata-city, Osaka, Japan
Site recruitment: Not reported
Osaka Saiseikai Suita hospital
Suita, Osaka, Japan
Site recruitment: Not reported
Shimane University Hospital
Izumo, Shimane, Japan
Site recruitment: Not reported
Tokyo Medical And Dental University Medical Hospital
Bunkyō, Tokyo, Japan
Site recruitment: Not reported
Fukuiken Saiseikai Hospital
Fukui, Japan
Site recruitment: Not reported
Gifu Municipal Hospital
Gifu, Japan
Site recruitment: Not reported
Kumamoto Shinto General Hospital
Kumamoto, Japan
Site recruitment: Not reported
University Hospital,Kyoto Prefectural University of Medicine
Kyoto, Japan
Site recruitment: Not reported
Niigata University Medical & Dental Hospital
Niigata, Japan
Site recruitment: Not reported
Saga University Hospital
Saga, Japan
Site recruitment: Not reported
Yamagata University Hospital
Yamagata, Japan
Site recruitment: Not reported
Phylasis Clinicas Research
Cuautitlan Izcalli, Mexico City, Mexico
Site recruitment: Not reported
Grupo Medico Camino Sc
Mexico City, Mexico City, Mexico
Site recruitment: Not reported
Christus Muguerza Hospital Sur
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported
Centro de Investigación y Gastroenterología
Cuauhtémoc, Mexico
Site recruitment: Not reported
Synexus Polska Sp. z o.o. Oddzial w Warszawie
Warsaw, Masovian Voivodeship, Poland
Site recruitment: Not reported
Synexus Polska Oddział w Lodzi
Lodz, Łódź Voivodeship, Poland
Site recruitment: Not reported
Clínica Juaneda
Palma de Mallorca, Balears [Baleares], Spain
Site recruitment: Not reported
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Site recruitment: Not reported
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Comunidad de, Spain
Site recruitment: Not reported
Instituto de Ciencias Médicas
Alicante, Spain
Site recruitment: Not reported
Hospital Universitario Puerta de Hierro Majadahonda
Madrid, Spain
Site recruitment: Not reported
Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)
Seville, Spain
Site recruitment: Not reported
Hospital Universitario Virgen Del Rocio
Seville, Spain
Site recruitment: Not reported
Queen Elizabeth Hospital Birmingham
Birmingham, England, United Kingdom
Site recruitment: Not reported
Synexus North East Clinical Research Centre
Hexham, England, United Kingdom
Site recruitment: Not reported
Royal London Hospital
London, England, United Kingdom
Site recruitment: Not reported
St. George's Hospital
London, England, United Kingdom
Site recruitment: Not reported
Synexus Clinical Research Centre - Lancashire
Chorley, Lancashire, United Kingdom
Site recruitment: Not reported
King's College Hospital
London, London, City of, United Kingdom
Site recruitment: Not reported
Queen's Medical Centre, Nottingham University Hospitals
Nottingham, Nottinghamshire, United Kingdom
Site recruitment: Not reported
John Radcliffe Hospital
Headington, Oxford, United Kingdom
Site recruitment: Not reported
Synexus North Teesside Clinical Research Centre
Stockton-on-Tees, Stockton-on-Tees, United Kingdom
Site recruitment: Not reported
Imperial College London - St Mary's Hospital
London, Westminster, United Kingdom
Site recruitment: Not reported
Synexus Midlands Clinical Research Centre
Birmingham, United Kingdom
Site recruitment: Not reported
Aintree University Hospital NHS Foundation Trust
Liverpool, United Kingdom
Site recruitment: Not reported
Synexus Manchester Clinical Research Centre
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

ClinicalTrials.gov · NCT06788626 · Registry updated: 2025-01-23

Condition / research focus: Acute Ischemic Stroke; Large Vessel Occlusion; Neuroprotective Drugs; Endovascular Treatment
Sponsor: Wei Hu
Countries with listed sites: China
Registry dates and results: Start: 2025-02. Completion: 2028-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide 0.5 mg (drug)
Standard medical treatment (other)

Where the study takes place — 1 listed sites

The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care

ClinicalTrials.gov · NCT05205928 · Registry updated: 2025-01-22

Condition / research focus: Type 1 Diabetes; Diabetes Mellitus, Type 1
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Countries with listed sites: Canada
Registry dates and results: Start: 2022-10-02. Completion: 2024-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy (drug)

Where the study takes place — 1 listed sites

Research Institute of the McGill University Health Centre
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Patients with Type 2 Diabetes.

ClinicalTrials.gov · NCT06017544 · Registry updated: 2025-01-20

Condition / research focus: Diabetes Mellitus, Type 2; Myocardial Infarction
Sponsor: University of Campania Luigi Vanvitelli
Countries with listed sites: Italy
Registry dates and results: Start: 2017-01-01. Completion: 2024-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PCI (procedure)

Where the study takes place — 1 listed sites

Celestino Sardu
Naples, Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 22:03 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableRecruitingINTERVENTIONAL

Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus

ClinicalTrials.gov · NCT05662189 · Registry updated: 2025-03-18

Condition / research focus: Type1diabetes; Type2diabetes; Pre Diabetes; Hyperinsulinism
Sponsor: Azienda Ospedaliero-Universitaria di Parma
Countries with listed sites: Italy
Registry dates and results: Start: 2022-03-15. Completion: 2025-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

68Ga-exendin-4 (drug)
mixed meal test (other)

Where the study takes place — 1 listed sites

Azienda Ospedaliero Universitaria di Parma
Parma, Pr, Italy
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

ClinicalTrials.gov · NCT04172441 · Registry updated: 2025-03-14

Condition / research focus: Congenital Hyperinsulinism
Sponsor: Zealand Pharma
Countries with listed sites: Germany · Israel · United Kingdom · United States
Registry dates and results: Start: 2020-06-19. Completion: 2022-03-07 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

dasiglucagon (drug) — also listed as: ZP4207
Placebo (drug)

Where the study takes place — 6 listed sites

Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Cook Children's Medical Center
Fort Worth, Texas, United States
Site recruitment: Not reported
University Children's Hospital
Düsseldorf, Germany
Site recruitment: Not reported
University Hospital, Magdeburg
Magdeburg, Germany
Site recruitment: Not reported
Hadassah Medical Center
Jerusalem, Israel
Site recruitment: Not reported
Manchester University NHS Foundation Trust
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableWithdrawnINTERVENTIONAL

An Exploratory Study of 68Ga-DOTA-SEMA in Preoperative Precise Imaging of Patients with Glucagon-Like Peptide-1 Receptor (GLP1R) Positive Insulinomas

ClinicalTrials.gov · NCT06759740 · Registry updated: 2025-03-14

Condition / research focus: Hypoglycaemia
Sponsor: The Affiliated Hospital Of Southwest Medical University
Countries with listed sites: China
Registry dates and results: Start: 2026-01. Completion: 2026-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

68Ga-DOTA-SEMA (radiation)

Where the study takes place — 1 listed sites

The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

ClinicalTrials.gov · NCT06515418 · Registry updated: 2025-03-13

Condition / research focus: Obesity
Sponsor: BioAge Labs, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2024-06-27. Completion: 2025-02-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral Azelaprag (BGE-105) (drug) — also listed as: BGE-105
Oral Placebo for Azelaprag (BGE-105) (drug) — also listed as: Placebo
Tirzepatide (drug)
Tirzepatide Placebo (drug)

Where the study takes place — 14 listed sites

Site 110
Mesa, Arizona, United States
Site recruitment: Not reported
Site 107
Los Angeles, California, United States
Site recruitment: Not reported
Site 103
Montclair, California, United States
Site recruitment: Not reported
Site 105
Spring Valley, California, United States
Site recruitment: Not reported
Site 100
Louisville, Kentucky, United States
Site recruitment: Not reported
Site 101
Marrero, Louisiana, United States
Site recruitment: Not reported
Site 112
Boston, Massachusetts, United States
Site recruitment: Not reported
Site 111
Troy, Michigan, United States
Site recruitment: Not reported
Site 113
City of Saint Peters, Missouri, United States
Site recruitment: Not reported
Site 106
Butte, Montana, United States
Site recruitment: Not reported
Site 109
Fargo, North Dakota, United States
Site recruitment: Not reported
Site 108
Beachwood, Ohio, United States
Site recruitment: Not reported
Site 102
Dallas, Texas, United States
Site recruitment: Not reported
Site 104
St. George, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

ClinicalTrials.gov · NCT03158805 · Registry updated: 2025-03-12

Condition / research focus: Bipolar Disorder; Obesity
Sponsor: Lindner Center of HOPE
Countries with listed sites: United States
Registry dates and results: Start: 2017-04-26. Completion: 2023-01-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

LIRAGLUTIDE (drug) — also listed as: Saxenda
Placebo (other)

Where the study takes place — 1 listed sites

Lindner Center of HOPE
Mason, Ohio, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies

ClinicalTrials.gov · NCT05920889 · Registry updated: 2025-03-07

Condition / research focus: Stroke; Stroke, Acute; Stroke, Ischemic; Brain Diseases
Sponsor: Chinese University of Hong Kong
Countries with listed sites: China · Hong Kong
Registry dates and results: Start: 2023-08-01. Completion: 2024-10-25 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide (drug)

Where the study takes place — 2 listed sites

Linyi People's Hospital
Linyi, Shangdong, China
Site recruitment: Not reported
Chinese University of Hong Kong
Hong Kong, Hong Kong
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2Active, not recruitingINTERVENTIONAL

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

ClinicalTrials.gov · NCT06565611 · Registry updated: 2025-03-06

Condition / research focus: Obesity
Sponsor: Palatin Technologies, Inc
Countries with listed sites: United States
Registry dates and results: Start: 2024-08-05. Completion: 2025-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

bremelanotide (drug)
tirzepatide (drug)

Where the study takes place — 4 listed sites

University Clinical Research-DeLand LLC, d/b/a Accel Research
DeLand, Florida, United States
Site recruitment: Not reported
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported
Coastal Carolina Research Center
North Charleston, South Carolina, United States
Site recruitment: Not reported
Lynn Institute of Chattanooga
Chattanooga, Tennessee, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Chronic Dorzagliatin on Insulin and Incretin Function in Intermediate Hyperglycemia and Type 2 Diabetes

ClinicalTrials.gov · NCT06671340 · Registry updated: 2025-03-04

Condition / research focus: Diabetes Mellitus; Prediabetes / Type 2 Diabetes
Sponsor: Elaine Chow
Countries with listed sites: Hong Kong
Registry dates and results: Start: 2025-04-02. Completion: 2026-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dorzagliatin (drug)

Where the study takes place — 1 listed sites

Phase 1 Clinical Trial Centre
Hong Kong, Hong Kong
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Liraglutide and Peripheral Artery Disease

ClinicalTrials.gov · NCT04881110 · Registry updated: 2025-03-03

Condition / research focus: Type 2 Diabetes; Peripheral Arterial Disease
Sponsor: University of Campania Luigi Vanvitelli
Countries with listed sites: Italy
Registry dates and results: Start: 2021-02-01. Completion: 2022-12-31 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug) — also listed as: Intervention group
Control (other) — also listed as: Control group

Where the study takes place — 1 listed sites

Unit of Endocrinology and Metabolic Diseases and Unit of Diabetes, University of Campania Luigi Vanvitelli
Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableRecruitingINTERVENTIONAL

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

ClinicalTrials.gov · NCT05501483 · Registry updated: 2025-02-26

Condition / research focus: Type 2 Diabetes
Sponsor: Karolinska Institutet
Countries with listed sites: Sweden
Registry dates and results: Start: 2023-02-08. Completion: 2032-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pioglitazone 45 mg (drug)
Empagliflozin 25 MG (drug)
Semaglutide 7 MG (drug)

Where the study takes place — 1 listed sites

Karolinska University Hospital
Stockholm, Sweden
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4WithdrawnINTERVENTIONAL

Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity

ClinicalTrials.gov · NCT06009653 · Registry updated: 2025-02-25

Condition / research focus: Obesity; Metabolic Disease
Sponsor: Washington University School of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2023-09-13. Completion: 2024-05-29 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Standard Care (behavioral)
Culturally-tailored dietary and behavioral intensive lifestyle intervention (behavioral)
Placebo (drug)
Tirzepatide (drug)

Where the study takes place — 1 listed sites

Sansum Diabetes Research Institute
Santa Barbara, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Early Phase 1CompletedINTERVENTIONAL

Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects

ClinicalTrials.gov · NCT03682172 · Registry updated: 2025-02-17

Condition / research focus: Effect of Glucagon-like Peptide 2 on Gallbladder Motility
Sponsor: Steno Diabetes Center Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2018-05-01. Completion: 2020-07-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GLP-2 (1pmol/kg/min) (drug)
GLP-2 (10pmol/kg/min) (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen
Hellerup, Capital Region, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

ClinicalTrials.gov · NCT05203237 · Registry updated: 2025-02-17

Condition / research focus: Weight Loss; NASH
Sponsor: Viking Therapeutics, Inc.
Countries with listed sites: Australia
Registry dates and results: Start: 2021-12-14. Completion: 2024-12-03 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

VK2735 (biological)
Placebo (biological)
VK2735 Placebo (drug)
VK2735 Drug (drug)

Where the study takes place — 1 listed sites

Viking Clinical Site
Adelaide, South Australia, Australia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3RecruitingINTERVENTIONAL

Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes

ClinicalTrials.gov · NCT06825182 · Registry updated: 2025-02-13

Condition / research focus: Type 2 Diabetes Mellitus
Sponsor: Nanjing First Hospital, Nanjing Medical University
Countries with listed sites: China
Registry dates and results: Start: 2024-11-07. Completion: 2025-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Outpatient newly diagnosed type 2 diabetes subjects (drug)
Inpatient newly diagnosed type 2 diabetes subjects (drug)

Where the study takes place — 1 listed sites

Nanjing First Hostital
Nanjing, Jiangsu, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists

ClinicalTrials.gov · NCT06818292 · Registry updated: 2025-02-10

Condition / research focus: Healthy
Sponsor: Nils Opel
Countries with listed sites: Germany
Registry dates and results: Start: 2024-10-21. Completion: 2024-12-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (biological) — also listed as: GLP-1 Agonist
Placebo (biological)

Where the study takes place — 1 listed sites

Department of Psychiatry and Psychotherapy, University Hospital Jena
Jena, Thuringia, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2RecruitingINTERVENTIONAL

Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov · NCT05268237 · Registry updated: 2025-02-06

Condition / research focus: Diabete Type 2
Sponsor: Biolingus
Countries with listed sites: Hong Kong
Registry dates and results: Start: 2023-04-25. Completion: 2026-03 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Clinical Trials Unit, Chinese University of Hong Kong
Hong Kong, Hong Kong
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

ClinicalTrials.gov · NCT04166773 · Registry updated: 2025-01-24

Condition / research focus: Nonalcoholic Steatohepatitis
Sponsor: Eli Lilly and Company
Countries with listed sites: Belgium · France · Israel · Italy · Japan · Mexico · Poland · Spain · United Kingdom · United States
Registry dates and results: Start: 2019-11-19. Completion: 2024-01-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)

Where the study takes place — 112 listed sites

University of Alabama-The Kirklin Clinic
Birmingham, Alabama, United States
Site recruitment: Not reported
Synexus Clinical Research US, Inc.
Chandler, Arizona, United States
Site recruitment: Not reported
Fresno Clinical Research Center
Fresno, California, United States
Site recruitment: Not reported
National Research Institute - Huntington Park
Huntington Park, California, United States
Site recruitment: Not reported
UCSD - Altman Clinical and Translational Research Institute (ACTRI)
La Jolla, California, United States
Site recruitment: Not reported
National Research Institute - Wilshire
Los Angeles, California, United States
Site recruitment: Not reported
Catalina Research Institute, LLC
Montclair, California, United States
Site recruitment: Not reported
Diabetes Medical Center of California
Northridge, California, United States
Site recruitment: Not reported
Velocity Clinical Research, Panorama City
Panorama City, California, United States
Site recruitment: Not reported
Inland Empire Clinical Trials, LLC
Rialto, California, United States
Site recruitment: Not reported
Velocity Clinical Research, Santa Ana
Santa Ana, California, United States
Site recruitment: Not reported
Excel Medical Clinical Trials
Boca Raton, Florida, United States
Site recruitment: Not reported
Alliance for Multispecialty Research, LLC
Coral Gables, Florida, United States
Site recruitment: Not reported
Research Centers of America ( Hollywood )
Hollywood, Florida, United States
Site recruitment: Not reported
East Coast Institute for Research, LLC
Jacksonville, Florida, United States
Site recruitment: Not reported
IHS Health Research
Kissimmee, Florida, United States
Site recruitment: Not reported
Accel Research Sites - Maitland Clinical Research Unit
Maitland, Florida, United States
Site recruitment: Not reported
Clinical Pharmacology of Miami
Miami, Florida, United States
Site recruitment: Not reported
The Center for Digestive Health
Orlando, Florida, United States
Site recruitment: Not reported
Synexus Clinical Research US, Inc.
Orlando, Florida, United States
Site recruitment: Not reported
Synexus Clinical Research US, Inc.
The Villages, Florida, United States
Site recruitment: Not reported
Synexus Clinical Research
Chicago, Illinois, United States
Site recruitment: Not reported
Indiana University Health Hospital
Indianapolis, Indiana, United States
Site recruitment: Not reported
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, United States
Site recruitment: Not reported
Cotton O'Neil Clinical Research Center
Topeka, Kansas, United States
Site recruitment: Not reported
Alliance for Multispecialty Research, LLC
Wichita, Kansas, United States
Site recruitment: Not reported
Tandem Clinical Research
Marrero, Louisiana, United States
Site recruitment: Not reported
The National Diabetes & Obesity Research Institute
Biloxi, Mississippi, United States
Site recruitment: Not reported
Southern Therapy and Advanced Research (STAR) LLC
Jackson, Mississippi, United States
Site recruitment: Not reported
Buffalo Clinical and Translational Research Center
Buffalo, New York, United States
Site recruitment: Not reported
NYU Langone Health
New York, New York, United States
Site recruitment: Not reported
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Site recruitment: Not reported
Montefiore Medical Center
The Bronx, New York, United States
Site recruitment: Not reported
Diabetes & Endocrinology Consultants, PC
Morehead City, North Carolina, United States
Site recruitment: Not reported
Geisinger Medical Center
Danville, Pennsylvania, United States
Site recruitment: Not reported
WR-Clinsearch, LLC
Chattanooga, Tennessee, United States
Site recruitment: Not reported
Dallas Diabetes Research Center
Dallas, Texas, United States
Site recruitment: Not reported
Radiant Research - Dallas North
Dallas, Texas, United States
Site recruitment: Not reported
Liver Center of Texas, PLLC
Dallas, Texas, United States
Site recruitment: Not reported
Texoma Medical Center
Denison, Texas, United States
Site recruitment: Not reported
Texas Diabetes & Endocrinology, P.A.
Round Rock, Texas, United States
Site recruitment: Not reported
American Research Corporation at Texas Liver Institute
San Antonio, Texas, United States
Site recruitment: Not reported
Synexus Clinical Research US, Inc.
San Antonio, Texas, United States
Site recruitment: Not reported
Endeavor Clinical Trials
San Antonio, Texas, United States
Site recruitment: Not reported
National Clinical Research, Inc
Richmond, Virginia, United States
Site recruitment: Not reported
Virginia Commonwealth University (VCU) Medical Center
Richmond, Virginia, United States
Site recruitment: Not reported
Harborview Medical Center/University of Washington
Seattle, Washington, United States
Site recruitment: Not reported
Antwerp University Hospital
Edegem, Antwerpen, Belgium
Site recruitment: Not reported
UZ Brussel
Brussels, Bruxelles-Capitale, Région de, Belgium
Site recruitment: Not reported
UZ Gent
Ghent, Oost-Vlaanderen, Belgium
Site recruitment: Not reported
UZ Leuven
Leuven, Vlaams-Brabant, Belgium
Site recruitment: Not reported
AZ Delta vzw
Roeselare, West-Vlaanderen, Belgium
Site recruitment: Not reported
CHU Bordeaux Haut-Leveque
Pessac, Aquitaine, France
Site recruitment: Not reported
Groupe Hospitalier Mutualiste Les Portes du Sud
Vénissieux, Auvergne-Rhône-Alpes, France
Site recruitment: Not reported
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren
Limoges, Haute-Vienne, France
Site recruitment: Not reported
Centre Hospitalier Universitaire d'Angers
Angers, Maine-et-Loire, France
Site recruitment: Not reported
Centre Hospitalier Lyon Sud
Pierre-Bénite, Rhône, France
Site recruitment: Not reported
Pitie Salpetriere University Hospital
Paris, France
Site recruitment: Not reported
Hôpital Saint Antoine
Paris, France
Site recruitment: Not reported
Sheba Medical Center
Ramat Gan, Central District, Israel
Site recruitment: Not reported
Hadassah Medical Center
Jerusalem, Jerusalem, Israel
Site recruitment: Not reported
Shaare Zedek Medical Center
Jerusalem, Jerusalem, Israel
Site recruitment: Not reported
Rambam Health Care Campus
Haifa, Northern District, Israel
Site recruitment: Not reported
Galilee Medical Center
Nahariya, Northern District, Israel
Site recruitment: Not reported
Carmel Hospital
Haifa, Israel
Site recruitment: Not reported
A.O.U. Policlinico Paolo Giaccone
Palermo, Sicily, Italy
Site recruitment: Not reported
Azienda Ospedaliero Universitaria Ospedali Riuniti Di Foggia
Foggia, Italy
Site recruitment: Not reported
Ospedale Santa Maria Goretti
Latina, Italy
Site recruitment: Not reported
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Italy
Site recruitment: Not reported
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
Torino, Italy
Site recruitment: Not reported
Aichi Medical University Hospital
Nagakute-shi, Aichi-ken, Japan
Site recruitment: Not reported
JCHO Hokkaido Hospital
Sapporo, Hokkaido, Japan
Site recruitment: Not reported
Yokohama City University Hospital
Yokohama, Kanagawa, Japan
Site recruitment: Not reported
National Hospital Organization Yokohama Medical Center
Yokohama, Kanagawa, Japan
Site recruitment: Not reported
JADECOM Nara City Hospital
Nara, Nara, Japan
Site recruitment: Not reported
Hirakata kohsai Hospital
Higashi-cho, Hirakata-city, Osaka, Japan
Site recruitment: Not reported
Osaka Saiseikai Suita hospital
Suita, Osaka, Japan
Site recruitment: Not reported
Shimane University Hospital
Izumo, Shimane, Japan
Site recruitment: Not reported
Tokyo Medical And Dental University Medical Hospital
Bunkyō, Tokyo, Japan
Site recruitment: Not reported
Fukuiken Saiseikai Hospital
Fukui, Japan
Site recruitment: Not reported
Gifu Municipal Hospital
Gifu, Japan
Site recruitment: Not reported
Kumamoto Shinto General Hospital
Kumamoto, Japan
Site recruitment: Not reported
University Hospital,Kyoto Prefectural University of Medicine
Kyoto, Japan
Site recruitment: Not reported
Niigata University Medical & Dental Hospital
Niigata, Japan
Site recruitment: Not reported
Saga University Hospital
Saga, Japan
Site recruitment: Not reported
Yamagata University Hospital
Yamagata, Japan
Site recruitment: Not reported
Phylasis Clinicas Research
Cuautitlan Izcalli, Mexico City, Mexico
Site recruitment: Not reported
Grupo Medico Camino Sc
Mexico City, Mexico City, Mexico
Site recruitment: Not reported
Christus Muguerza Hospital Sur
Monterrey, Nuevo León, Mexico
Site recruitment: Not reported
Centro de Investigación y Gastroenterología
Cuauhtémoc, Mexico
Site recruitment: Not reported
Synexus Polska Sp. z o.o. Oddzial w Warszawie
Warsaw, Masovian Voivodeship, Poland
Site recruitment: Not reported
Synexus Polska Oddział w Lodzi
Lodz, Łódź Voivodeship, Poland
Site recruitment: Not reported
Clínica Juaneda
Palma de Mallorca, Balears [Baleares], Spain
Site recruitment: Not reported
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria, Spain
Site recruitment: Not reported
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Comunidad de, Spain
Site recruitment: Not reported
Instituto de Ciencias Médicas
Alicante, Spain
Site recruitment: Not reported
Hospital Universitario Puerta de Hierro Majadahonda
Madrid, Spain
Site recruitment: Not reported
Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)
Seville, Spain
Site recruitment: Not reported
Hospital Universitario Virgen Del Rocio
Seville, Spain
Site recruitment: Not reported
Queen Elizabeth Hospital Birmingham
Birmingham, England, United Kingdom
Site recruitment: Not reported
Synexus North East Clinical Research Centre
Hexham, England, United Kingdom
Site recruitment: Not reported
Royal London Hospital
London, England, United Kingdom
Site recruitment: Not reported
St. George's Hospital
London, England, United Kingdom
Site recruitment: Not reported
Synexus Clinical Research Centre - Lancashire
Chorley, Lancashire, United Kingdom
Site recruitment: Not reported
King's College Hospital
London, London, City of, United Kingdom
Site recruitment: Not reported
Queen's Medical Centre, Nottingham University Hospitals
Nottingham, Nottinghamshire, United Kingdom
Site recruitment: Not reported
John Radcliffe Hospital
Headington, Oxford, United Kingdom
Site recruitment: Not reported
Synexus North Teesside Clinical Research Centre
Stockton-on-Tees, Stockton-on-Tees, United Kingdom
Site recruitment: Not reported
Imperial College London - St Mary's Hospital
London, Westminster, United Kingdom
Site recruitment: Not reported
Synexus Midlands Clinical Research Centre
Birmingham, United Kingdom
Site recruitment: Not reported
Aintree University Hospital NHS Foundation Trust
Liverpool, United Kingdom
Site recruitment: Not reported
Synexus Manchester Clinical Research Centre
Manchester, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

ClinicalTrials.gov · NCT06788626 · Registry updated: 2025-01-23

Condition / research focus: Acute Ischemic Stroke; Large Vessel Occlusion; Neuroprotective Drugs; Endovascular Treatment
Sponsor: Wei Hu
Countries with listed sites: China
Registry dates and results: Start: 2025-02. Completion: 2028-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide 0.5 mg (drug)
Standard medical treatment (other)

Where the study takes place — 1 listed sites

The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3CompletedINTERVENTIONAL

Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care

ClinicalTrials.gov · NCT05205928 · Registry updated: 2025-01-22

Condition / research focus: Type 1 Diabetes; Diabetes Mellitus, Type 1
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Countries with listed sites: Canada
Registry dates and results: Start: 2022-10-02. Completion: 2024-06-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy (drug)

Where the study takes place — 1 listed sites

Research Institute of the McGill University Health Centre
Montreal, Quebec, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Patients with Type 2 Diabetes.

ClinicalTrials.gov · NCT06017544 · Registry updated: 2025-01-20

Condition / research focus: Diabetes Mellitus, Type 2; Myocardial Infarction
Sponsor: University of Campania Luigi Vanvitelli
Countries with listed sites: Italy
Registry dates and results: Start: 2017-01-01. Completion: 2024-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

PCI (procedure)

Where the study takes place — 1 listed sites

Celestino Sardu
Naples, Naples, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →